An atlas of depression

Abstract

Depressive disorders constitute a significant global health burden, representing a leading cause of disability and mortality worldwide. Characterized by persistent low mood, anhedonia, and diminished energy, these conditions often demonstrate high comorbidity with anxiety syndromes, requiring precise diagnostic differentiation through established clinical criteria. Epidemiological data show a lifetime prevalence of approximately 15%, with women disproportionately affected and a rising incidence observed in younger populations. The etiology of depression is multifactorial, involving a complex interplay between genetic predispositions, dysregulation of neurotransmitters such as serotonin and norepinephrine, and psychosocial stressors like bereavement and social exclusion. Effective clinical management encompasses acute, continuation, and maintenance phases to mitigate the high risk of relapse and recurrence. Therapeutic interventions include a diverse range of pharmacotherapies—including selective serotonin reuptake inhibitors, tricyclic antidepressants, and newer dual-acting agents—alongside physical treatments such as electroconvulsive therapy and light therapy for seasonal patterns. Psychological modalities, specifically cognitive-behavioral, interpersonal, and problem-solving therapies, serve as critical adjuncts for addressing maladaptive cognitions and social deficits. Given that suicide is a major risk factor, particularly following deliberate self-harm or during depressive episodes, rigorous risk assessment and the use of safe, well-tolerated treatments are paramount. Additionally, clinicians must address the physiological impacts of the disorder, including sleep disturbances and sexual dysfunction, to improve long-term patient outcomes and reduce the societal economic burden. – AI-generated abstract.